New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT06644300
Summary
This is the first study in humans testing a new drug called BM230 for people with advanced solid tumors that have a specific marker called HER2. The main goal is to find a safe dose and see how the body handles the drug. It's for patients whose cancer has continued to grow despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan Unversity Zhongshan Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
Icon Cancer Centre - South Brisbane
RECRUITINGBrisbane, Queensland, 4101, Australia
-
Monash Health - Monash Medical Centre
RECRUITINGMonash, Victoria, Australia
-
Southern Oncology Clinical Research Unit
RECRUITINGAdelaide, South Australia, Australia
-
The first Affiliated Hospital of Bengbu Medical University
RECRUITINGBengbu, Anhui, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.